Headlines
Lilly sues four compounders over copies of weight-loss drugs
Published by Global Banking and Finance Review
Posted on April 23, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on April 23, 2025
(Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines.
Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps.
Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.
Lilly's lawsuits, to be filed in California, name Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds, accusing them of selling tirzepatide knockoffs — including versions with additives or in oral form — without clinical evidence of safety or effectiveness.
Indianapolis-based Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide.
Earlier this month, the company sued two other compounders and said it would send about fifty cease and desist letters, asking companies to confirm that they have already ceased mass compounding.
Compounding facilities create medicines by combining, mixing or altering drug ingredients.
(Reporting by Christy Santhosh in Bengaluru; Editing by Nivedita Bhattacharjee)